NCT03626467View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017

PHASE4CompletedINTERVENTIONAL

Enrollment

158

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

July 14, 2021

Study Completion Date

July 14, 2021

Conditions

HIV Infections

Interventions

BIOLOGICAL

HPV9v

Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24

Trial Locations (3)

28034

Hospital Ramón y Cajal, Madrid

Unknown

Hospital Fundación Jimenez Díaz, Madrid

Hospital La Paz, Madrid

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fundacion SEIMC-GESIDA

OTHER

NCT03626467 - A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017 | Biotech Hunter | Biotech Hunter